Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma

Department of Dermatology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
Journal of Dermatological Case Reports 06/2012; 6(2):52-3. DOI: 10.3315/jdcr.2012.1099
Source: PubMed

ABSTRACT The classic Kaposi sarcoma is most common in the Mediterranean population over 50 years of age and presents with reddish-brown papules and nodules particularly on the lower limbs. Treatment depends on the clinical presentation and extension of lesions. Imiquimod is as an immune response modifier with antiangiogenic activity.
We present a 74-year-old man with classic Kaposi sarcoma who had multiple, small, violaceous papules and nodules on the trunk and extremities with a history of 14 years. He complained particularly from plantar hyperkeratotic painful nodules. Treatment with imiquimod 5% cream under occlusion resulted with almost complete regression within 12 weeks. No local or systemic side effects were observed.
Topical imiquimod was a safe and effective therapy in our patient with classic Kaposi sarcoma.

Download full-text


Available from: Işil Inanir, Jul 24, 2014
58 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response modifier activity, when topically used. This characteristic property of imiquimod has led to its use in a number of applications in dermatology, particularly in cutaneous malignancies, where it has been found to be effective and safe. Currently, additional mechanisms for its activity in actinic keratosis, basal cell carcinoma, and invasive squamous cell carcinoma have been elucidated. Its usage for cutaneous metastasis in breast cancer has been a further addition to its therapeutic armamentarium recently.
    Indian Journal of Pharmacology 07/2015; 47(4):354-9. DOI:10.4103/0253-7613.161249 · 0.69 Impact Factor